Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerecor Inc. stock logo
CERC
Cerecor
$11.83
-0.4%
$2.60
$1.98
$4.50
$1.14B1.441.27 million shs323,673 shs
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$11.50
-1.0%
$9.44
$4.64
$23.33
$142.41M3.08127,128 shs283,518 shs
Harrow, Inc. stock logo
HROW
Harrow
$44.34
-2.3%
$37.28
$20.85
$59.23
$1.68B0.33522,687 shs756,242 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.27
+2.4%
$1.30
$1.13
$2.55
N/A0.4363,303 shs31,850 shs
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
$0.00
$0.02
$0.04
$603K3.7912.96 million shs3,000 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerecor Inc. stock logo
CERC
Cerecor
+4.85%+9.19%+33.56%+156.03%+26.14%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-1.03%+21.05%+24.73%+39.56%-76.69%
Harrow, Inc. stock logo
HROW
Harrow
-2.29%+12.48%+15.98%+44.62%-2.18%
MediciNova, Inc. stock logo
MNOV
MediciNova
+2.42%+3.25%-3.05%-1.55%-18.06%
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerecor Inc. stock logo
CERC
Cerecor
$11.83
-0.4%
$2.60
$1.98
$4.50
$1.14B1.441.27 million shs323,673 shs
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$11.50
-1.0%
$9.44
$4.64
$23.33
$142.41M3.08127,128 shs283,518 shs
Harrow, Inc. stock logo
HROW
Harrow
$44.34
-2.3%
$37.28
$20.85
$59.23
$1.68B0.33522,687 shs756,242 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.27
+2.4%
$1.30
$1.13
$2.55
N/A0.4363,303 shs31,850 shs
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
$0.00
$0.02
$0.04
$603K3.7912.96 million shs3,000 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerecor Inc. stock logo
CERC
Cerecor
+4.85%+9.19%+33.56%+156.03%+26.14%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-1.03%+21.05%+24.73%+39.56%-76.69%
Harrow, Inc. stock logo
HROW
Harrow
-2.29%+12.48%+15.98%+44.62%-2.18%
MediciNova, Inc. stock logo
MNOV
MediciNova
+2.42%+3.25%-3.05%-1.55%-18.06%
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cerecor Inc. stock logo
CERC
Cerecor
0.00
N/AN/AN/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.10
Buy$49.00326.09% Upside
Harrow, Inc. stock logo
HROW
Harrow
2.88
Moderate Buy$64.6745.84% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
3.00
Buy$7.00451.18% Upside
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MNOV, CRBP, PLXP, CERC, and HROW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00
9/12/2025
Harrow, Inc. stock logo
HROW
Harrow
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/11/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/27/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
8/14/2025
Harrow, Inc. stock logo
HROW
Harrow
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/14/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$62.00 ➝ $63.00
8/13/2025
Harrow, Inc. stock logo
HROW
Harrow
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $64.00
8/6/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$56.00 ➝ $53.00
7/30/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy$28.00
7/24/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
7/12/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M170.24N/AN/A$0.22 per share54.00
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/A$11.69 per shareN/A
Harrow, Inc. stock logo
HROW
Harrow
$199.61M8.22$0.13 per share331.87$1.95 per share22.74
MediciNova, Inc. stock logo
MNOV
MediciNova
$1MN/AN/AN/A$1.07 per shareN/A
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
$4.54M0.00N/AN/A$1.30 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%11/6/2025 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.250.00110.85N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.25N/AN/AN/AN/A-23.12%-21.85%11/12/2025 (Estimated)
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/A

Latest MNOV, CRBP, PLXP, CERC, and HROW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.07-$0.07N/A-$0.07N/A$0.14 million
8/11/2025Q2 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.01$0.24+$0.23$0.13$64.23 million$63.74 million
8/5/2025Q2 2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.55-$1.44+$0.11-$1.44N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
9.21
9.21
Harrow, Inc. stock logo
HROW
Harrow
0.78
0.62
0.58
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
13.26
13.26
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
N/A
4.79
4.28

Institutional Ownership

CompanyInstitutional Ownership
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
21.19%

Insider Ownership

CompanyInsider Ownership
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.60%
Harrow, Inc. stock logo
HROW
Harrow
15.16%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
8.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4012.26 million11.81 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18037.00 million31.39 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
10N/AN/AOptionable
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
1629.14 million26.53 millionNot Optionable

Recent News About These Companies

PLXp/USD - Pullix US Dollar
Protalix Biotherapeutics Inc (PLX)
Vertex Pharmaceuticals Inc VRTX
Vietnam National Petroleum Group (PLX)
PLx Pharma Inc (PLXPQ)
PLXPQ PLx Pharma Inc.
Why PLx Pharma Shares Are Nosediving Today
PLx Pharma Inc. Receives Nasdaq Delisting Notice
Short Volatility Alert: Plx Pharma Inc
PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript
PLx Pharma down after Q3 revenue fell 94% Y/Y

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cerecor stock logo

Cerecor NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Corbus Pharmaceuticals stock logo

Corbus Pharmaceuticals NASDAQ:CRBP

$11.50 -0.12 (-1.03%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$11.65 +0.15 (+1.30%)
As of 09/19/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Harrow stock logo

Harrow NASDAQ:HROW

$44.34 -1.04 (-2.29%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$44.49 +0.15 (+0.34%)
As of 09/19/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.27 +0.03 (+2.42%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$1.26 -0.01 (-0.71%)
As of 09/19/2025 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

PLx Pharma stock logo

PLx Pharma NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.